drugset / Trial / NCT06818812
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.
Timeline
- Start
- 2025-03-27
- Primary completion
- 2027-03-27
- Completion
- 2027-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCB186748 | Unknown | — | — |
| Background | Cetuximab | Monoclonal antibody | — | — |